Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

F0260000

Fluphenazine decanoate

European Pharmacopoeia (EP) Reference Standard

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C32H44F3N3O2S
Número de CAS:
5002-47-1
Peso molecular:
591.77
Número CE:
225-672-4
Número MDL:
MFCD00798504
Código UNSPSC:
41116107
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

fluphenazine

fabricante / nombre comercial

EDQM

aplicaciones

pharmaceutical (small molecule)

Formato

neat

cadena SMILES

FC(F)(F)c1cc2c(cc1)Sc3c(cccc3)N2CCCN4CCN(CC4)CCOC(=O)CCCCCCCCC

InChI

1S/C32H44F3N3O2S/c1-2-3-4-5-6-7-8-14-31(39)40-24-23-37-21-19-36(20-22-37)17-11-18-38-27-12-9-10-13-29(27)41-30-16-15-26(25-28(30)38)32(33,34)35/h9-10,12-13,15-16,25H,2-8,11,14,17-24H2,1H3

Clave InChI

VIQCGTZFEYDQMR-UHFFFAOYSA-N

Categorías relacionadas

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Fluphenazine decanoate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

Y0000009

Fluphenazine enantate, European Pharmacopoeia (EP) Reference Standard

Y0000298

Fluphenazine octanoate, European Pharmacopoeia (EP) Reference Standard

Y0000299

Fluphenazine sulfoxide, European Pharmacopoeia (EP) Reference Standard

Y0000708

Fluphenazine impurity mixture, European Pharmacopoeia (EP) Reference Standard

F0280000

Fluphenazine dihydrochloride, European Pharmacopoeia (EP) Reference Standard

1282004

Fluphenazine hydrochloride, United States Pharmacopeia (USP) Reference Standard

1280803

Fluphenazine decanoate dihydrochloride, United States Pharmacopeia (USP) Reference Standard

1281001

Fluphenazine enanthate dihydrochloride, United States Pharmacopeia (USP) Reference Standard

PHR1792

Fluphenazine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

BP167

Fluphenazine hydrochloride, British Pharmacopoeia (BP) Reference Standard

1282026

Fluphenazine Related Compound B, United States Pharmacopeia (USP) Reference Standard

Pictogramas

Skull and crossbonesHealth hazard
GHS06,GHS08

Palabra de señalización

Danger

Frases de peligro

H300,H361

Clasificaciones de peligro

Acute Tox. 2 Oral - Repr. 2

Código de clase de almacenamiento

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Janice Charles et al.
Australian family physician, 35(3), 88-89 (2006-03-10)
The BEACH program, a continuous national study of general practice activity in Australia, gives us an overview of consultations involving the management of psychoses. In this analysis we have included schizophrenia, affective disorders/bipolar, organic psychoses, and senile psychoses, with undefined
Rajaprabhakaran Rajarethinam et al.
The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 10(4 Pt 2), 416-419 (2009-06-06)
Aripiprazole, a partial dopamine agonist has been reported to help reduce symptoms of tardive dyskinesia (TD). In a prospective, open label study of a series of cases, we examined the effectiveness of aripiprazole in reducing TD symptoms. Six clinically stable
Mis-deca-n identity?
Elizabeth A S Giugni et al.
The Medical journal of Australia, 187(6), 370-370 (2007-09-19)
Zana Stanković et al.
Psychiatria Danubina, 20(1), 42-52 (2008-04-01)
To compare patient's attitudes, demographic, clinical characteristics, psychopathology, insight and type of antipsychotic therapy in compliant and non-compliant outpatients with schizophrenia; to explore correlations between patient's attitudes and related variables. A sample of 44 outpatients of both genders (> 60
Martin Turner et al.
International clinical psychopharmacology, 19(4), 241-249 (2004-06-18)
Long-acting injectable risperidone was assessed in schizophrenia patients who were symptomatically stable on conventional depot antipsychotics and who were then switched to long-acting risperidone. Participants in this open-label, multicentre, 12-week trial had received flupenthixol decanoate, fluphenazine decanoate, haloperidol decanoate, or
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico